本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

CRISPR Therapeutics AG

53.35
+0.82001.56%
成交量:150.78萬
成交額:7,956.16萬
市值:50.84億
市盈率:-9.56
高:54.38
開:51.36
低:51.22
收:52.53
52周最高:78.48
52周最低:30.04
股本:9,530.02萬
流通股本:9,053.30萬
量比:1.98
換手率:1.67%
股息:- -
股息率:- -
每股收益(TTM):-5.5830
每股收益(LYR):-4.3416
淨資產收益率:-25.33%
總資產收益率:-13.28%
市淨率:2.65
市盈率(LYR):-12.29

資料載入中...

2024/08/05

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/06/03

重要事件披露

Form 8-K - Current report
2024/05/23

重要事件披露

Form 8-K - Current report
2024/05/08

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/05/08

重要事件披露

Form 8-K - Current report
2024/04/16

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/04/10

超過5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/03/22

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/03/15

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/02/21

年度報告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2024/02/21

重要事件披露

Form 8-K - Current report
2024/02/16

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/02/14

重要事件披露

Form 8-K - Current report
2024/02/13

重要事件披露

Form 8-K - Current report
2024/02/12

超過5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/09

超過5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/05

超過5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/01/30

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/01/30

超過5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/01/17

關聯方擬減持公告

Form 144 - Report of proposed sale of securities